Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ATNM – Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc.
ATNM
$1.42
Name : Actinium Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $44,298,176.00
EPSttm : -1.47
finviz dynamic chart for ATNM
Actinium Pharmaceuticals, Inc.
$1.42
12.35%
$0.2

Float Short %

4.72

Margin Of Safety %

Put/Call OI Ratio

0.02

EPS Next Q Diff

0.15

EPS Last/This Y

-0.21

EPS This/Next Y

0.71

Price

1.46

Target Price

5

Analyst Recom

1.4

Performance Q

-24.87

Relative Volume

12.3

Beta

-0.29

Ticker: ATNM




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02ATNM1.6150.030.001996
2025-06-03ATNM1.680.030.002066
2025-06-04ATNM1.710.030.002090
2025-06-05ATNM1.680.030.002103
2025-06-06ATNM1.820.030.002065
2025-06-09ATNM1.930.030.002066
2025-06-10ATNM1.760.030.002071
2025-06-11ATNM1.650.030.002090
2025-06-12ATNM1.580.030.002090
2025-06-13ATNM1.490.030.002104
2025-06-16ATNM1.5250.030.002132
2025-06-17ATNM1.440.030.002132
2025-06-18ATNM1.450.030.002139
2025-06-20ATNM1.4850.030.002194
2025-06-23ATNM1.540.030.002028
2025-06-24ATNM1.680.030.002051
2025-06-25ATNM1.6350.020.002266
2025-06-26ATNM1.60.020.002268
2025-06-27ATNM1.420.020.002284
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02ATNM1.617.2- -1.48
2025-06-03ATNM1.687.2- -1.48
2025-06-04ATNM1.717.2- -1.48
2025-06-05ATNM1.697.2- -1.48
2025-06-06ATNM1.827.2- -1.48
2025-06-09ATNM1.947.2- -1.48
2025-06-10ATNM1.757.2- -1.48
2025-06-11ATNM1.667.2- -1.48
2025-06-12ATNM1.597.2- -1.48
2025-06-13ATNM1.497.2- -1.48
2025-06-16ATNM1.537.2- -1.48
2025-06-17ATNM1.437.2- -1.48
2025-06-18ATNM1.467.2- -1.48
2025-06-20ATNM1.507.2- -1.48
2025-06-23ATNM1.547.2- -1.48
2025-06-24ATNM1.697.2- -1.48
2025-06-25ATNM1.647.2- -1.48
2025-06-26ATNM1.617.2- -1.48
2025-06-27ATNM1.467.2- -1.48
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02ATNM0.000.246.01
2025-06-03ATNM0.000.246.01
2025-06-04ATNM0.000.246.01
2025-06-05ATNM0.000.246.01
2025-06-06ATNM0.000.246.01
2025-06-09ATNM0.000.236.01
2025-06-11ATNM0.000.236.35
2025-06-12ATNM0.000.236.35
2025-06-13ATNM0.000.236.35
2025-06-16ATNM0.000.236.35
2025-06-17ATNM0.000.236.35
2025-06-18ATNM0.000.236.35
2025-06-19ATNM0.000.236.35
2025-06-20ATNM0.000.236.35
2025-06-24ATNM0.00-0.446.35
2025-06-25ATNM0.00-0.446.35
2025-06-26ATNM0.00-0.444.72
2025-06-27ATNM0.00-0.444.72
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.51

Avg. EPS Est. Current Quarter

-0.35

Avg. EPS Est. Next Quarter

-0.36

Insider Transactions

Institutional Transactions

-0.44

Beta

-0.29

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

5

Growth Score

21

Sentiment Score

36

Actual DrawDown %

92.5

Max Drawdown 5-Year %

-94.1

Target Price

5

P/E

Forward P/E

PEG

P/S

P/B

1.72

P/Free Cash Flow

EPS

-1.47

Average EPS Est. Cur. Y​

-1.48

EPS Next Y. (Est.)

-0.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

12.3

Return on Equity vs Sector %

-201

Return on Equity vs Industry %

-183.2

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.25

EBIT Estimation

Actinium Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 31
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
stock quote shares ATNM – Actinium Pharmaceuticals Inc Stock Price stock today
news today ATNM – Actinium Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ATNM – Actinium Pharmaceuticals Inc yahoo finance google finance
stock history ATNM – Actinium Pharmaceuticals Inc invest stock market
stock prices ATNM premarket after hours
ticker ATNM fair value insiders trading